Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target
Epstein Barr virus (EBV)-associated lymphoproliferative diseases (LPDs) express all EBV latent antigens (type III latency) in immunodeficient patients and limited antigens (type I and II latencies) in immunocompetent patients. Post-transplantation lymphoproliferative disease (PTLD) is the prototype...
Main Authors: | Tse, Eric, Kwong, Yok-Lam |
---|---|
Format: | Online |
Language: | English |
Published: |
Nature Publishing Group
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4314579/ |
Similar Items
-
Epstein-Barr virus induced hemophagocytic lymphohistiocytosis in X-linked lymphoproliferative disease
by: Sankararaman, Senthilkumar, et al.
Published: (2014) -
Epstein–Barr virus-positive T/NK-cell lymphoproliferative disorders
by: Cai, Qingqing, et al.
Published: (2015) -
Induction and progression of human lymphoproliferative lesions by Epstein-Barr virus.
by: Chappuis, B B, et al.
Published: (1990) -
Molecular signature of Epstein Barr virus-positive Burkitt lymphoma and post-transplant lymphoproliferative disorder suggest different roles for Epstein Barr virus
by: Navari, Mohsen, et al.
Published: (2014) -
Synchronous tuberculosis, Epstein-Barr virus-associated lymphoproliferative disorder and cytomegalovirus infection in an allogeneic transplant recipient: a case report
by: Ostendorf, Benjamin Nils, et al.
Published: (2014)